Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

A quinazoline, photosensitivity technology for pharmaceutical applications in the treatment of photosensitive epilepsy (PSE), capable of addressing birth defects and more

Inactive Publication Date: 2014-06-25
NOVARTIS AG
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Valproate can also cause birth defects and should not be given during pregnancy, which is a major concern in photosensitive epilepsy because it is primarily diagnosed in young women

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
  • Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
  • Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0165] Compound C-7, used in the studies described below, is an orally active compound of general formula (I).

[0166]The study used the IPS / PPR paradigm. This is a multicenter, non-randomized, single-blind, within-subject, placebo-controlled proof-of-concept study conducted to evaluate a single oral dose of Compound C-7 in inhibiting photoictal responses in PSE patients ( PPR) or the effect of reducing the standard photoparoxysmal response range (SPR). Photosensitivity was detected using electroencephalography (EEG) measurements in subjects exposed to intermittent photostimulation (IPS). This EEG response is the photoparoxysmal response (PPR). For research purposes, it is desired that the PPR is triggered by the IPS, not the seizure. The SPR for each patient is the number of standard visual stimulus frequencies (in Hertz) to which the patient is sensitive, between the lower and upper thresholds. Test 14 frequencies (2-60Hz). The onset and duration of response (PPR inhib...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy.

Description

technical field [0001] The present invention relates to the pharmaceutical use of 1H-quinazoline-2,4-dione, its pharmaceutically acceptable salts, and its prodrugs specifically for the treatment of photosensitive epilepsy (PSE). Background of the invention [0002] Epilepsy is one of the most common neurological disorders, with a lifetime prevalence of more than 1% of the world's population. Despite the availability of approximately 20 antiepileptic drugs (AEDs), there is still a high medical need for improved epilepsy treatment, as approximately 30-40% of patients are inadequately controlled or affected by drug side effects. [0003] Photosensitive epilepsy (PSE) is a rare form of reflex epilepsy in which seizures are elicited in photosensitive individuals by periodic visual stimuli such as flashes of light or flickering lights, or regular patterns such as bars or grids. Said modes are usually high in brightness contrast (bright flashes of alternating light and dark, or wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517C07D239/96C07D403/04C07D405/04A61P25/08
CPCC07D239/96A61K31/517A61K45/06A61P25/08A61K2300/00
Inventor K·库彻D·约翰斯G·因贝特
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap